Canaccord Genuity raised its price target for Compass Pathways to $20.00 from $18.00. The firm maintained a Buy rating on the shares.
Analysts anticipate positive Phase 3 data for the COMP360 depression treatment in early Q3 2026. The company expects to complete a new drug application by the fourth quarter of 2026.
Potential approval for COMP360 could occur as early as late 2026 or early 2027. High investor enthusiasm persists in the sector following positive data from a competitor. The stock traded at $13.58 at the time of the report.